IND Swift Limited — Fexofenadine Exporter Profile
Indian Pharmaceutical Exporter · #2 for Fexofenadine · $16.9M export value · DGFT Verified
IND Swift Limited is the #2 Indian exporter of Fexofenadine with $16.9M in export value and 524 verified shipments. IND Swift Limited holds a 13.3% market share in Fexofenadine exports across 12 countries. The company exports 13 pharmaceutical products worth $36.7M across 9 therapeutic categories.
IND Swift Limited — Fexofenadine Export Profile: Buyers & Destinations
Where Does IND Swift Limited Export Fexofenadine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| IRELAND | $6.8M | 318 | 60.8% |
| AUSTRALIA | $1.6M | 54 | 14.2% |
| UNITED KINGDOM | $941.6K | 26 | 8.4% |
| CHILE | $494.7K | 26 | 4.4% |
| SINGAPORE | $392.2K | 15 | 3.5% |
| MALAYSIA | $333.0K | 17 | 3.0% |
| SOUTH AFRICA | $311.7K | 36 | 2.8% |
| UNITED ARAB EMIRATES | $224.7K | 19 | 2.0% |
| VIETNAM, DEMOCRATIC REP. OF | $36.7K | 4 | 0.3% |
| TAJIKISTAN | $25.8K | 2 | 0.2% |
IND Swift Limited exports Fexofenadine to 13 countries. The largest destination is IRELAND accounting for 60.8% of IND Swift Limited's Fexofenadine shipments, followed by AUSTRALIA (14.2%) and UNITED KINGDOM (8.4%). These destinations reflect IND Swift Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Fexofenadine from IND Swift Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CHANELLE MEDICAL | IRELAND | $6.8M | 313 |
| APOTEX PTY LTD | AUSTRALIA | $904.0K | 37 |
| KENT PHARMA UK LTD | UNITED KINGDOM | $710.3K | 17 |
| APOTEX PTY LTD. | AUSTRALIA | $574.6K | 13 |
| SYNERRV SDN BHD. | MALAYSIA | $333.0K | 17 |
| ASCEND LABORATORIES SPA | CHILE | $328.5K | 16 |
| GOLDPLUS UNIVERSAL PTE LTD | SINGAPORE | $320.6K | 13 |
| KENT PHARMA UK LIMITED | UNITED KINGDOM | $231.3K | 9 |
| TRINITY PHARMA (PTY) LTD. | SOUTH AFRICA | $174.1K | 27 |
| BIOVENTURE HEALTHCARE FZE | UNITED ARAB EMIRATES | $139.2K | 15 |
IND Swift Limited supplies Fexofenadine to 25 buyers globally. The largest buyer is CHANELLE MEDICAL (IRELAND), followed by APOTEX PTY LTD (AUSTRALIA) and KENT PHARMA UK LTD (UNITED KINGDOM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Fexofenadine Export Value and How Much Does IND Swift Limited Contribute?
India exported $81.9M worth of Fexofenadine through 4,236 shipments from 224 suppliers to 97 countries, serving 599 buyers globally. IND Swift Limited contributes $16.9M to this total, accounting for 13.3% of India's Fexofenadine exports. IND Swift Limited ships Fexofenadine to 13 countries through 25 buyers.
What Is the Average Shipment Value for IND Swift Limited's Fexofenadine Exports?
IND Swift Limited's average Fexofenadine shipment value is $32.2K per consignment, based on 524 shipments totaling $16.9M. The largest destination is IRELAND (60.8% of IND Swift Limited's Fexofenadine exports).
How Does IND Swift Limited Compare to Other Indian Fexofenadine Exporters?
IND Swift Limited ranks #2 among 224 Indian Fexofenadine exporters with a 13.3% market share. The top 3 exporters are IND SWIFT LIMITED ($14.6M), CIPLA LIMITED ($13.6M), DR.REDDY'S LABORATORIES LTD ($12.4M). IND Swift Limited processed 524 shipments to 12 destination countries.
What Fexofenadine Formulations Does IND Swift Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| APO HEALTH FEXOFENADINE 180 Mg(Fexofenad | $350.0K | 7 |
| ALTIFEX 180 MG(FEXOFENADINE HYDROCHLORID | $198.7K | 5 |
| TELFEXO 120 MG(FEXOFENADINE HYDROCHLORID | $187.6K | 5 |
| PIRILIEVE HAYFEVER RELIEF 120 MG FILM COATED TABLETS (FEXOFENADINE HYDROCHLORIDE120 MG FILM COATED TABLETS) | $150.0K | 3 |
| FEXOFENADINE HYDROCHLORIDE 180 MG (FEXOFENADINE HYDROCHLORIDE 180MG FILM COATEDTABLETS) (113310X3X10T)NOS | $150.0K | 3 |
| TELFEXO 180 MG (FEXOFENADINE HYDROCHLORIDE 180MG TABLETS) (139680X20=2793600NOS)NOS | $148.1K | 3 |
| TELFEXO 180 MG (FEXOFENADINE HYDROCHLORIDE 180MG TABLETS) (135730X20=2714600 NOS)NOS | $146.7K | 3 |
| TELFEXO 180MG(FEXOFENADINE HYDROC.180 MG)B.NO.UP11224 TO UP11524 MFG.APR/MAY-2024 EXP.MAR/APR-2027(135540X20=2710800NOS) | $141.4K | 3 |
| TELFEXO 180MG(FEXOFENADINE HYDROCHLORIDE | $128.0K | 3 |
| TELFEXO 180 MG(FEXOFENADINE HYDROCHLORID | $124.3K | 3 |
IND Swift Limited exports 326 distinct Fexofenadine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is APO HEALTH FEXOFENADINE 180 Mg(Fexofenad with 7 shipments worth $350.0K.
Regulatory Requirements: Exporting Fexofenadine to Key Markets
What IND Swift Limited must comply with to export Fexofenadine to its top destination countries
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does IND Swift Limited Compare to Nearest Fexofenadine Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | IND SWIFT LIMITED ★ | $14.6M | 524 | 12 | $27.8K |
| 3 | CIPLA LIMITED | $13.6M | 921 | 7 | $14.8K |
| 4 | DR.REDDY'S LABORATORIES LTD | $12.4M | 249 | 5 | $50.0K |
IND Swift Limited ranks #2 among 224 Indian Fexofenadine exporters. Average shipment value of $27.8K compared to the market average of $365.5K. The closest competitors by value are CIPLA LIMITED and DR.REDDY'S LABORATORIES LTD.
Which Indian Ports Ship Fexofenadine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 569 | 13.4% |
| JNPT/ NHAVA SHEVA SEA | 385 | 9.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 362 | 8.5% |
| NHAVA SHEVA SEA (INNSA1) | 350 | 8.3% |
| HYDERABAD ICD | 229 | 5.4% |
| CHAWAPAYAL ICD | 186 | 4.4% |
| JNPT | 161 | 3.8% |
| CHAWAPAYAL ICD (INCPR6) | 142 | 3.4% |
What Other Antihistamines & Allergy Products Does IND Swift Limited Export?
IND Swift Limited also exports these antihistamines & allergy products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on IND Swift Limited's Fexofenadine Exports
Ind-Swift Laboratories' export operations have been influenced by recent geopolitical developments. The Israel-Iran conflict has heightened security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and increased freight rates by 40–50% on key India–Europe routes, impacting the company's logistics and cost structures. (livemint.com)
Conversely, the India–European Union Free Trade Agreement (India–EU FTA), concluded in January 2026, is poised to benefit Indian pharmaceutical exporters. The agreement eliminates tariffs on most European pharmaceutical imports, enhancing the competitiveness of Indian products in the EU market. This development presents an opportunity for Ind-Swift Laboratories to expand its footprint in Europe. (en.wikipedia.org)
In the United States, the reshoring of pharmaceutical manufacturing and potential imposition of tariffs on imports pose challenges for Indian exporters. While there are currently no import duties on Indian pharmaceutical products entering the US, the introduction of tariffs could affect the profitability of low-margin generic drugs, potentially leading to market exits. (cfo.economictimes.indiatimes.com)
IND Swift Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Indian pharmaceutical exporters. Ind-Swift Laboratories has demonstrated a commitment to quality by adhering to Good Manufacturing Practices (GMP) as stipulated by the US FDA, WHO, and EU authorities. The company's manufacturing facilities in Punjab and Jammu have been inspected and approved by these regulatory bodies, facilitating access to regulated markets.
The evolving regulatory landscape, including the EU's Falsified Medicines Directive, necessitates continuous investment in quality systems and supply chain transparency. Ind-Swift Laboratories' focus on high-margin formulations underscores the importance of maintaining stringent quality standards to meet global regulatory requirements and sustain market access.
About IND Swift Limited
IND Swift Limited exports 13 products worth $36.7M. Beyond Fexofenadine, top products include Ramipril, Clarithromycin, Loratadine, Ezetimibe, Terbinafine. View the complete IND Swift Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Fexofenadine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Fexofenadine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: IND Swift Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 524 individual customs records matching IND Swift Limited exporting Fexofenadine, covering 326 formulations to 13 countries via 25 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 97+ countries, 599+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Fexofenadine Export Data from IND Swift Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for IND Swift Limited's Fexofenadine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
IND Swift Limited
Full Company Profile →
13 products · $36.7M total trade · 9 categories
Fexofenadine Stats
Company Overview
Top Products by IND Swift Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for IND Swift Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Fexofenadine. For current shipment-level data, contact TransData Nexus.